Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Johnson & Johnson is an impeccable dividend stock with a streak of 63 consecutive dividend raises. The company's long history ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...

SAN ANTONIO — Finding out you have a deadly disease is never a pleasant experience, But if you have a good support system and the right information about your illness, the direction you go could save ...

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

The Columbus startup received FDA approval and has a clinical trial underway for a therapy targeting acute lymphoblastic ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. UBS analyst ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...